Literature DB >> 25704415

The Charlson age comorbidity index predicts early mortality after surgery for pancreatic cancer.

Daniela Dias-Santos1, Cristina R Ferrone2, Hui Zheng3, Keith D Lillemoe2, Carlos Fernández-Del Castillo4.   

Abstract

BACKGROUND: Although operative resection represents the only hope for cure in pancreatic cancer, it is associated with significant morbidity and mortality. Furthermore, in some patients disease progression occurs very early postoperatively and no tangible benefit is seen from the operation. Identification of preoperative predictors of death within the first year of surgery could help in the counseling of patients diagnosed with pancreatic cancer.
METHODS: We studied retrospectively patients who underwent resection for pancreatic adenocarcinoma from 2002 to 2012. We calculated the age-adjusted Charlson Age Comorbidity Index (CACI) and used logistic regression models to determine predictors of mortality within 1 year of surgery. Kaplan-Meier curves and Cox proportional hazards models were developed to determine hazard ratios on survival.
RESULTS: Surgery with curative intent was performed in 497 patients; 136 (27%) died within the first year. A CACI score of >4 was predictive of increased duration of stay (P < .001), postoperative complications (P = .042), and mortality within 1 year of pancreatic resection (P < .001). A CACI score of ≥ 6 increased 3-fold the odds of death within the first year.
CONCLUSION: CACI is useful to predict outcome after pancreatectomy for pancreatic cancer. Patients with a high CACI score have a <50% likelihood of being alive 1 year postoperatively. This information should be used when considering the appropriateness of pancreatic resection in patients with multiple comorbidities.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25704415     DOI: 10.1016/j.surg.2014.12.006

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  31 in total

Review 1.  Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Davendra P S Sohal; Pamela B Mangu; Alok A Khorana; Manish A Shah; Philip A Philip; Eileen M O'Reilly; Hope E Uronis; Ramesh K Ramanathan; Christopher H Crane; Anitra Engebretson; Joseph T Ruggiero; Mehmet S Copur; Michelle Lau; Susan Urba; Daniel Laheru
Journal:  J Clin Oncol       Date:  2016-05-31       Impact factor: 44.544

2.  Role of Tumor-Associated Macrophages in the Clinical Course of Pancreatic Neuroendocrine Tumors (PanNETs).

Authors:  Lei Cai; Theodoros Michelakos; Vikram Deshpande; Kshitij S Arora; Teppei Yamada; David T Ting; Marty S Taylor; Carlos Fernandez-Del Castillo; Andrew L Warshaw; Keith D Lillemoe; Soldano Ferrone; Cristina R Ferrone
Journal:  Clin Cancer Res       Date:  2019-01-22       Impact factor: 12.531

3.  Volume-outcome relationships in pancreatoduodenectomy for cancer.

Authors:  Lydia G M van der Geest; L Bengt van Rijssen; I Quintus Molenaar; Ignace H de Hingh; Bas Groot Koerkamp; Olivier R C Busch; Valery E P P Lemmens; Marc G H Besselink
Journal:  HPB (Oxford)       Date:  2016-02-11       Impact factor: 3.647

4.  Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma.

Authors:  Vincent P Groot; Georgios Gemenetzis; Alex B Blair; Roberto J Rivero-Soto; Jun Yu; Ammar A Javed; Richard A Burkhart; Inne H M Borel Rinkes; I Quintus Molenaar; John L Cameron; Matthew J Weiss; Christopher L Wolfgang; Jin He
Journal:  Ann Surg       Date:  2018-03-23       Impact factor: 12.969

5.  The age-adjusted Charlson comorbidity index as a predictor of overall survival of surgically treated non-metastatic clear cell renal cell carcinoma.

Authors:  Ho Won Kang; Sung Min Kim; Won Tae Kim; Seok Joong Yun; Sang-Cheol Lee; Wun-Jae Kim; Eu Chang Hwang; Seok Ho Kang; Sung-Hoo Hong; Jinsoo Chung; Tae Gyun Kwon; Hyeon Hoe Kim; Cheol Kwak; Seok-Soo Byun; Yong-June Kim
Journal:  J Cancer Res Clin Oncol       Date:  2019-10-12       Impact factor: 4.553

6.  Minimally invasive distal pancreatectomy: greatest benefit for the frail.

Authors:  Ioannis T Konstantinidis; Aaron Lewis; Byrne Lee; Susanne G Warner; Yanghee Woo; Gagandeep Singh; Yuman Fong; Laleh G Melstrom
Journal:  Surg Endosc       Date:  2017-05-10       Impact factor: 4.584

7.  Malnutrition, frailty, and sarcopenia in pancreatic cancer patients: assessments and interventions for the pancreatic surgeon.

Authors:  Noah S Rozich; Caitlin E Jones; Katherine T Morris
Journal:  Ann Pancreat Cancer       Date:  2019-03-11

8.  Early Recurrence and Omission of Adjuvant Therapy after Pancreaticoduodenectomy Argue against a Surgery-First Approach.

Authors:  Brent T Xia; David A Habib; Vikrom K Dhar; Nick C Levinsky; Young Kim; Dennis J Hanseman; Jeffrey M Sutton; Gregory C Wilson; Milton Smith; Kyuran Ann Choe; Jeffrey J Sussman; Syed A Ahmad; Daniel E Abbott
Journal:  Ann Surg Oncol       Date:  2016-07-26       Impact factor: 5.344

Review 9.  Prognostic value of lymph node metastases detected during surgical exploration for pancreatic or periampullary cancer: a systematic review and meta-analysis.

Authors:  Lennart B van Rijssen; Poorvi Narwade; Nadine C M van Huijgevoort; Dorine S J Tseng; Hjalmar C van Santvoort; Isaac Q Molenaar; Hanneke W M van Laarhoven; Casper H J van Eijck; Olivier R C Busch; Marc G H Besselink
Journal:  HPB (Oxford)       Date:  2016-05-27       Impact factor: 3.647

10.  Relationship between Cancer Diagnosis and Complications Following Pancreatoduodenectomy for Duodenal Adenoma.

Authors:  Nina L Eng; Danielle E Mustin; Brendan P Lovasik; Michael K Turgeon; Adriana C Gamboa; Mihir M Shah; Kenneth Cardona; Juan M Sarmiento; Maria C Russell; Shishir K Maithel; Jeffrey M Switchenko; David A Kooby
Journal:  Ann Surg Oncol       Date:  2020-07-20       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.